A persistent misconception in biotech is that a first laboratory fails because the company succeeds too quickly. In practice, the opposite is often closer to the truth: many first labs are chosen for speed, affordability and immediate proof of concept, then asked to support a very different operating model within 18 to 36 months. The available evidence from incubator markets points in that direction. CBRE’s 2025 U.S. Life Sciences Incubator Survey found that most startups stay in incubator facilities for at least two years, while more than 60% of respondents said over half of their startups graduate from incubator status, and 83% said they actively help those companies secure their next lab or office. LabCentral’s latest impact data points to the same pattern at scale: since 2013 it has supported 278 companies that created 6,339 jobs, raised $18.4 billion, launched 132 clinical trials and occupied a network that now exceeds 243,000 sq ft. That is not a picture of companies finding a permanent first home. It is a picture of first labs acting as launchpads.
Cambridge intensifies that pattern because it compresses science, capital and property pressure into a single geography. Cambridge Enterprise reported in 2025 that the region’s active life sciences and deep tech company base had grown from 473 companies in 2015 to 848 in 2025, and that those early-stage companies had raised £7.9 billion since 2015. Savills, meanwhile, reported that take up across Cambridge reached 273,000 sq ft by the end of the first half of 2025, 33% above the five year average, with 705,000 sq ft of active requirements still in the market. In other words, more companies are being created, more capital is pursuing them, and more space is needed at the exact point when many founders discover that their first lab was sized for a seed story rather than a scaling business.
One reason this happens is that first labs are often procured under an incorrect optimisation logic. The initial brief is often to get into compliant wet lab space as fast as possible, close to talent and investors, with minimal upfront capital. Savills noted that the fitted flexible lab segment in the UK has been leasing quickly at sizes around 500 to 1,200 sq ft, which tells its own story about how small many entry level lab decisions are. That makes sense for a founding team with a narrow experimental plan, but it leaves little margin when assay complexity expands, sample storage multiplies, equipment arrives in waves, and the company needs write up, QA, data and operations functions that were not part of the original footprint. The result is not simply that the company grows. It is that the nature of the work changes faster than the space assumption.
The core biotech lab growth challenges are therefore usually infrastructural before they are numerical. Headcount matters, but bench density is only one variable. The real pressure points are utilities, environmental control, storage, contamination management, equipment adjacencies and the ability to segregate workflows. That is why purpose-built lab specifications look very different from standard commercial buildings. Knight Frank’s technical guidance notes that slab to slab height below 4.00m, commonly 3.75m in conventional offices, is already tight for lab conversion. The same source states that lab cooling loads are typically two to three times those allowed for in offices, and that laboratory buildings consume three to five times the energy of a standard office, with over 60% of that energy used in ventilation. It also points to a typical laboratory slab to slab design range of 4,200 to 4,500 mm and a typical ventilation requirement starting at a minimum of 6 air changes per hour, often rising well above that depending on use. A startup can appear to outgrow a lab “too early” simply because those technical thresholds were not embedded in the first decision.
South Cambridge Science Centre
This is also why office to lab conversion often proves less forgiving than founders expect. Cushman & Wakefield’s Constructing Science guidance was designed precisely because the market kept asking whether a given site or building could successfully work for laboratories. That guidance identifies structural vibration, floor loading, slab to slab heights, air changes, segregated drainage, power supply, waste treatment, laboratory gases and fume cupboards as core specification variables. It also observed active demand of more than 2 million sq ft across the Golden Triangle when the framework was launched, with almost no availability at the time. The point is not that conversions are impossible. It is that a startup can lock in spatial constraints very early if it chooses a first lab that meets today’s experimental requirement but cannot absorb tomorrow’s technical one.
The capital side of the equation is equally important. Lab space is expensive to adapt, and moving late is usually more expensive than moving deliberately. CBRE reported that life sciences fit out costs surged 20% to 25%, and that tenant improvement allowances across major life sciences markets rose by an average of 38% from 2021 levels. CBRE also notes that laboratory fit out costs typically range from $300 to $650 per sq ft, compared with $110 to $315 for standard office fit outs. Even allowing for regional variation, the directional point is clear: once a biotech must retrofit power, ventilation, drainage, gases and specialist equipment access under time pressure, the move becomes a capital event rather than a facilities event. That is why the question of When to move lab biotech operations is really a financing question disguised as an occupancy question.
The timing error founders may make is waiting for a hard physical failure rather than recognising a soft operational one. By the time freezers appear in corridors, analytical equipment is sharing rooms with sample preparation, quality documentation is being handled in improvised desk space, and every new hire requires a bench reshuffle, the move is already overdue. CBRE’s incubator survey is instructive here because it shows that incubator operators do not treat post incubator real estate as an afterthought. They treat it as part of company development. More than 60% of survey respondents reported that over half of their startups graduate from incubator status, and 83% assist with securing the next facility. That suggests an important market truth: experienced operators assume the first lab is temporary and plan the second one before the first becomes operationally constraining.
In Cambridge, that planning challenge has become more visible because the market is beginning to develop a real “grow on” layer between incubator space and a bespoke headquarters. Savills’ 2025 Cambridge market report said that 604,000 sq ft of laboratory space was available in the city by midyear, and that new completions including The Press and South Cambridge Science Centre added 203,000 sq ft of purpose-built laboratory enabled space to supply. The report also noted that the largest laboratory letting in the first half of 2025 was Frontier taking 18,000 sq ft at South Cambridge Science Centre on a shell and core basis to provide incubation space for portfolio companies. That detail matters because it shows investors themselves are treating next stage space as a strategic growth variable, not just a real estate transaction.
South Cambridge Science Centre fits this narrative subtly but quite precisely. Its official specification points to several characteristics that directly address the problem of startups outgrowing their first lab prematurely: wet lab or dry lab configuration for different occupier types, minimum VC A vibration criteria for sensitive equipment, clear 4.16m floor to underside of slab, fume hood extraction, ample risers, drainage points, two goods lifts, readiness for gas storage and standby generation, and the ability to accommodate a wide range of uses including microbiology, PCR, chemistry, flow cytometry, viral vector work and GMP. The scheme’s FAQ also says the layout can be subdivided down to about 5,000 sq ft and expanded upward from there. The importance of that is not promotional. It is structural. A building with those characteristics gives a scaling company more lab space flexibility than a smaller fitted starter suite or an office conversion with limited headroom and constrained services.
That is the real substance behind the phrase scaling lab space start up. It is about securing technical headroom, spatial adjacency and lease options before the science requires them urgently. Startups that manage this well usually make three moves earlier than their peers. First, they separate immediate fit from future fit and ask whether the building can absorb new equipment classes, new compliance requirements and new process steps. Second, they model the move timeline against scientific milestones rather than waiting for a lease event. Third, they prioritise lab space flexibility over cosmetic fit out because flexibility is what preserves momentum when biology, instrumentation or funding strategy changes. Those are not abstract real estate preferences. They are operational risk controls supported by what incubator and market data now show about graduation patterns and facilities demand.
The broader lesson is that founders should consider stop treating the first lab as a milestone and start treating it as a phase. In today’s biotech market, the first lab is usually a speed layer. The second lab is often the first one that can genuinely support scale. Cambridge’s growth data, the rise of flexible lab products, the technical realities of laboratory infrastructure, and the emergence of schemes such as South Cambridge Science Centre all point to the same conclusion: startups do not usually outgrow their first lab because they misread square footage. They outgrow it because they underestimate how quickly proof of concept science turns into operational science. When that shift is anticipated, the company tends to move on its own terms. When it is not, the move arrives as a disruption, usually at the most expensive possible moment.
